Skip to main content

Table 2 Summary of Ipilimumab Trials

From: Therapy for metastatic melanoma: the past, present, and future

Trial Patients RR%
(CR/PR)
PFS (months) OS
(years)
Number
(patients)
Summary
Phase 3
Hodi et al. [24]
Ipilimumab plus gp100
versus
Ipilimumab alone
versus
gp100 alone
previously treated metastatic melanoma
5.7
versus
10.9
versus
1.5
2.76
versus
2.86
versus
2.76
10.0
versus
10.1
versus
6.4
676 Ipilimumab with significant improvement in OS versus gp-100.
Phase 3
Robert et al. [23]
Ipilimumab plus dacarbazine
versus
dacarbazine in untreated metastatic melanoma
15.2
versus
10.3
Not stated 11.2
versus
9.1
502 Ipilimumab plus dacarbazine significantly with significant improvement in OS over dacarbazine.
Phase 2
Hersh et al. [40]
Ipilimumab
versus
Ipilimumab plus dacarbazine in chemotherapy naïve patients with metastatic melanoma
5.3
versus
14.3
Not stated 11.4
versus
14.4
72 Ipilimumab plus dacarbazine improved RR and OS compared to single agent ipilimumab.
  1. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.